AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 21 min read$CELC

Celcuity Inc. (CELC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Celcuity Inc. (CELC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Celcuity Appoints David Gryska To Its Board Of Directors Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board MINNEAPOLIS, October 2, 2026 — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and comm

Original reporting
SEC EDGAR 8-K
Published Oct 2, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CELC
Bullish
medium confidence
Mentioned
$CELC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CELCBullishLow
01

Why it matters

The appointment signals strengthened financial oversight as the company scales commercialization, which could reduce execution risk and support the stock.

02

Market read

A primary 8‑K filing reporting a board appointment for a small‑cap biotech; modest relevance for traders focused on micro‑cap governance news.

03

What to watch

Potential for future board‑level strategic shifts or financing initiatives not yet disclosed.

Relevance 6/10Novelty 5/10Timing: today

Background

Celcuity is a Nasdaq‑listed biotech focused on the pan‑PI3K/mTOR inhibitor gedatolisib (REVTORPYK). The company recently received its first FDA approval and is entering commercial launch.

Company-level read

Ticker impact

$CELCBullishMedium confidence
Context

Celcuity filed an 8‑K announcing the appointment of David W. Gryska to its Board of Directors.

Expected impact

modest upside as the market prices in added governance expertise

Evidence & confidence

The new director brings extensive financial and industry experience, supporting the commercial rollout of REVTORPYK; no immediate financial transaction is disclosed.

Market effects

Sector

Adds credibility to Celcuity's biotech governance, modestly supportive for the sector's small‑cap pipeline companies.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low; the news is company‑specific and does not affect global markets.

Counterpoint

What could challenge this read

Board changes rarely move micro‑cap stocks; investors may ignore the appointment.

Key entities

  • Person
    David W. Gryska

    New board member, former CFO of Incyte and Celgene.

  • Person
    Brian Sullivan

    CEO of Celcuity, announced the appointment.

Read at source← All news

Related articles

OCT 23
$CELCMedAI 8/10

Celcuity reports phase 1b prostate cancer trial results

Celcuity Inc. (CELC) reported Phase 1b/2 trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer. The study showed median radiographic progression-free survival of 15.7 months for patients who received prior abiraterone and 9.1 months for those who received prior enzalutamide. The company plans to begin the Phase 2 portion of the study in the first half of 2027.

investing.com2 min
OCT 22
High

Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data

Celcuity Inc. shares rose 7.78% after Cantor Fitzgerald initiated coverage with an overweight rating and a $140 price target, citing growth potential of its breast cancer drug, Revtorpyk. The company will present key clinical data at the ESMO Congress this weekend. Analysts are bullish, with price targets ranging from $130 to $177, despite a 50% stock decline over six months.

ibtimes.com.au2 min
OCT 3
$CELCMed

How REVTORPYK Launch Will Impact Celcuity (CELC) Investors

Celcuity (CELC) launched REVTORPYK in the US for certain breast cancer patients and filed an FDA application to expand its use. The company is investing in access infrastructure, and investors will watch early prescription trends and FDA review progress. Celcuity's consensus revenue and earnings forecasts for 2029 are US$817.9 million and US$267.5 million, respectively, up from current losses. The appointment of David W. Gryska to the board may impact financial oversight and execution.

simplywall.st2 min